Metformin use in patients with type 2 diabetes mellitus is associated with reduced risk of deep vein thrombosis: a non-randomized, pair-matched cohort study

Table 1 Baseline characteristics of the study population

	Metformin
	No (N = 7778)	Yes (N = 7167)	P value
Age, years	57.72 ± 13.37	57.70 ± 12.55	0.937
Male gender	4095 (52.6)	3808 (53.1)	0.565
Hypertension	1885 (24.2)	1695 (23.7)	0.413
CAD	671 (8.6)	535 (7.5)	0.010
Hyperlipidemia	905 (11.6)	849 (11.8)	0.708
Atrial fibrillation	69 (0.9)	35 (0.5)	0.005
Cancer	372 (3.8)	308 (4.3)	0.155
Fracture	538 (6.9)	364 (5.1)	<0.001
Major surgery	405 (5.2)	321 (4.5)	0.04
*Medications*
Aspirin	696 (8.9)	692 (9.7)	0.144
Clopidogrel	12 (0.2)	8 (0.1)	0.625
Warfarin	31 (0.4)	36 (0.5)	0.409
Statin	263 (3.4)	342 (4.8)	<0.001
HRT	45 (0.6)	54 (0.8)	0.203
*Other anti-hyperglycemic agents*
SU	7652 (98.4)	6941 (96.8)	<0.001
Meglitinide	2117 (27.2)	626 (8.7)	<0.001
α-glucosidase Inhibitor	2629 (33.8)	938 (13.1)	<0.001
TZD	2663 (34.2)	1188 (16.6)	<0.001
Insulin	5377 (69.1)	2342 (32.7)	<0.001
Kind of drug used	2.63 ± 0.84	2.68 ± 0.85	<0.001

Data are the mean ± SD and n (%).
CAD indicates coronary artery disease; HRT, hormone replacement therapy; SU, sulfonylurea; TZD, Thiazolidinediones.
Fracture includes traumatic or pathological fracture involving upper or lower limbs, spine and pelvis.
Major surgery includes cardiothoracic, abdominal, pelvic surgery or orthopedic surgery of lower limbs.

ISSN: 1471-2261